The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

November 14, 2021 • By Ashraf Raslan, MD, Dorian Infantino, MD, Roman Zuckerman, DO, & Daniel Berlin, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
The biopsy of the right temporal artery with hematoxylin and eosin (H&E) staining was unremarkable.

Figure 1. The biopsy of the right temporal artery with hematoxylin and eosin (H&E) staining was unremarkable.

Sarah2 / shutterstock.com

You Might Also Like
  • Giant Cell Arteritis
  • New Insights into the Management of Giant Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment
Explore This Issue
November 2021

Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being permanent vision loss.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The diagnosis is suspected clinically based on characteristic symptoms and laboratory findings, and confirmed histologically by temporal artery biopsy.

A classical presentation is easy to recognize when a patient older than 50 presents with a new-onset headache along with other characteristic findings, such as jaw claudication, symptoms of polymyalgia rheumatica (PMR) and elevated inflam­matory markers. In clinical practice, however, GCA often presents diagnostic and management challenges.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

These challenges arise from different factors, including:

  • An atypical presentation (e.g., no headaches or atypical headaches, normal inflammatory markers or rare presenting symptoms, such as tongue or limb claudication, chronic cough, vertigo or oculomotor nerve palsy);
  • A negative temporal artery biopsy despite the high probability of the disease based on clinical presentation. In this case, the clinician has to make the difficult decision to continue high-dose steroid therapy, which comes with the potential of serious adverse effects, or to stop therapy and risk serious complications, such as permanent vision loss;
  • Temporal arteritis due to another form of systemic vasculitis, such as anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis or polyarteritis nodosa (PAN); or
  • Intolerance to high-dose steroid therapy.

We present a case that highlights some of these challenges and provide some clinical pearls that can help in the diagnosis and management of GCA.

Case Presentation

Our patient is a 78-year-old woman with a past medical history of hypertension and osteoporosis. She initially presented to the emergency department with new-onset neck pain and headache that started after a long bus ride one week earlier.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The pain started as a right-sided pos­terior neck pain, which radiated to the right occipital scalp and then anteriorly toward the right frontal area. She described the pain as intermittent, sharp, shooting and severe, at times.

She had no constitutional symptoms, jaw claudication or proximal myalgias. Her neurological examination was normal. Magnetic resonance imaging (MRI) of the brain was obtained because of her acute-onset, severe headache, but was unremarkable. MRI of the cervical spine showed age-related degenerative changes.

Her laboratory evaluation was significant for a markedly elevated erythrocyte sedimentation rate (ESR) of 73 mm/hr (reference range [RR]: 0–15 mm/hr) and C-reactive protein (CRP) of 87 mg/L (RR: <5–10 mg/L).

She underwent a unilateral right temporal artery biopsy (see Figures 1&2, above and opposite) and was started on 60 mg of prednisone daily for suspected GCA. Her headaches mildly improved, but her temporal artery biopsy result was did not demonstrate evidence of vasculitis. Given her negative biopsy results, GCA was considered unlikely, and the prednisone was tapered off over two weeks.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: case report, Giant Cell Arteritis, tocilizumabIssue: November 2021

You Might Also Like:
  • Giant Cell Arteritis
  • New Insights into the Management of Giant Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)